Abstract: Provided are a semiconductor structure and a manufacturing method thereof. The manufacturing method of the semiconductor structure includes the following. A gate structure is formed on a substrate. A tilt implanting process is performed to implant group IV elements into the substrate to form a doped region, and the doped region is located on two sides of the gate structure and partially located under the gate structure. A part of the substrate on two sides of the gate structure is removed to form a first recess. A cleaning process is performed on the surface of the first recess. A wet etching process is performed on the first recess to form a second recess. A semiconductor layer is formed in the second recess.

Abstract: A laser slicing apparatus, in which a laser module provides a laser beam, and a light splitting element of a focusing lens set splits the laser beam into a plurality of focused laser beams to form a plurality of induce lines having first laser modified cracks in a modified layer at a predetermined depth inside a substrate. A rotating module rotates the light splitting element with an angle, and the light splitting element converts the focused laser beams according to this angle to form a plurality of modified groups between the induce lines. Each modified group includes a plurality of modified lines having second laser modified cracks, and the first laser modified cracks and the second laser modified cracks are connected to each other to form a continuous laser modified crack in the modified layer at the predetermined depth inside the substrate, thereby speeding up the laser slicing production.

Abstract: Provided are the use of the compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-ethyl-N,N?-bis(ethylene)phosphoramidate, or a pharmaceutically acceptable salt, isotopic variant or solvate thereof in the manufacture of a medicament for treating cancer, and a composition which comprises the above compound and at least one anti-cancer drug.

Abstract: A pharmaceutical composition, including a compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-N ethyl-N,N?-bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological agent, and its medical use are provided.

Abstract: An in vitro method for screening a testing compound to evaluate its potential as a liver drug is provided. The method includes applying the testing compound to cells of an isolated human liver tumor cell line, named as ITRI-H16, measuring a cell viability of the cells and determining the effect of the testing compound on the cells by calculating a half maximal inhibitory concentration (IC50) of the testing compound.

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract: An isolated human liver tumor cell line is provided and is named as ITRI-H16, and which was deposited in the Food Industry Research and Development Institute with the accession number BCRC960432 on Nov. 7, 2011. A method of an agent screening is also provided. The method includes providing the isolated human liver tumor cell line ITRI-H16 and treating an interest compound to the ITRI-H16 cell line to determine an effect of the interesting compound on the ITRI-H16 cell line.

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract: The disclosure provides a pharmaceutical composition for promoting wound healing, including an effective amount of a Sambucus plant or an Isatis plant as an active ingredient for promoting wound healing; and a pharmaceutically acceptable carrier or medium, wherein the Sambucus plant is Sambucus formosana Nakai, and the Isatis plant is Isatis indigotica Fort.

Abstract: A steam massaging device includes a steam generator, a main tube and a massaging means. The steam generator comprises a boiler, a seal lid and a steam outlet. The steam outlet has one end located above the boiler and the other end connected to one end of the main tube. The main tube has the other end connected to the massaging means for conducting steam to an interior of the massaging means. The massaging means comprises at least one massaging plate assembly or one massaging rod assembly. The massaging plate assemblies are interconnected, and the massaging rod is connected to the massaging plate assembly/assemblies so that steam can flow through them. The massaging device may be used to massaging the back and waist as well as the soles.

Abstract: A door opening warning system device actuatable when a door of a car is going to be opened, including a non-remote control type contact switch for providing a "POWER OFF" signal, a flash signal power feed controller, a contact switch for providing a "POWER OFF" signal, a flash device and warning lights. The non-remote control type contact switch may be installed at the ignition key or other suitable positions of the car. The flash signal power feed controller and the contact switch for providing the "POWER OFF" signal are connected via circuitry to the flash device and warning lights of the car. When the ignition key is turned to an "OFF" position or contact switches of other warning system devices are contacted before the driver opens the door to get off, power is connected to cause the warning lights to flash. When the doors are closed or locked, the contact switch for providing a "POWER OFF" signal will be actuated to cut off power supply.